The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Award Winners (O001-O007) - Takeaways - MDSpire

The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Award Winners (O001-O007)

  • November 5, 2025

  • 0 min

Share

  • 1

    Ghosal hematodiaphyseal dysplasia (GHD) is a rare disorder characterized by severe anemia and painful cortical hypertrophy of long bones.

  • 2

    NSAIDs have been shown to be an effective first-line treatment for GHD, providing significant hemoglobin and platelet responses without major adverse effects.

  • 3

    Patients treated with NSAIDs achieved hemoglobin responses within a median of 3 months and platelet responses within 2 months.

  • 4

    Bone marrow biopsies in GHD patients revealed severe hypoplasia and interstitial edema, complicating diagnosis and treatment.

  • 5

    Screening for TBXAS1 mutations should be standard in inherited bone marrow failure syndromes, especially before hematopoietic stem cell transplantation.

Original Source(s)

The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Award Winners (O001-O007)

  • November 5, 2025

Related Content

Molecular Identification of HTLV-1 and HCV Infections in Sickle Cell Disease Patients Undergoing Multiple Transfusions in Kinshasa: A Case Study of CMMASS

Utilizing Erythrocyte Lifespan as a Predictor for Moderate to Severe Anemia in Patients with Advanced Gastric Cancer Following Anti-Tumor Treatments: A Prospective Investigation

Fistulizing Crohn's disease

Luca Stocchi, M.D., a colorectal surgeon at Mayo Clinic in Florida, presents a surgical case involving a 53-year-old male with long-standing, fistulizing Crohn's disease. The patient had a prior open ileocolic resection and subsequently developed progressive weight loss and anemia.

  • January 5, 2026

  • 1 min